Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05740748
Other study ID # ESR-22-21828
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 1, 2023
Est. completion date December 30, 2024

Study information

Verified date February 2023
Source McMaster University
Contact Gail M Gauvreau, PhD
Phone 9055259140
Email gauvreau@mcmaster.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.


Description:

The proposed study will address whether tezepelumab has the unique ability to improve AHR in participants with mild allergic asthma. This is a phase 2 multi-centre randomized double-blind placebo-controlled parallel-group study to examine the effects of 24 weeks tezepelumab 210 mg sc q4wks on methacholine airway hyperresponsiveness in participants with mild allergic asthma, stratified for sex and sensitivity to seasonal allergens. There are 9 study visits over a period of 27 weeks (Figure 1). Study procedures performed at Weeks -1, 8, 16 and 24 will be divided across 2 visits at least 48 hours apart for measurement of AHR to methacholine first, and mannitol at least 48 hours later. The screening period at Week -1 will determine eligibility. At Week -1, eligible allergic mild asthmatic participants will be randomized 1:1 to placebo or tezepelumab 210 mg subcutaneous administered monthly for a total of 24 weeks. AHR will be measured by methacholine and mannitol challenges at baseline (Week -1) performed at least 48 hours apart. Changes in AHR response will be measured by repeat methacholine and mannitol challenges at Weeks 8, 16 and 24.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 34
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures 2. Male and female 18 through 65 years of age 3. Positive skin-prick test to a common aeroallergen 4. Methacholine PD20 = 200mcg 5. Mannitol DRR = 42.3mg/FEV1 %f all (equivalent to PD15 = 635mg) 6. Baseline FEV1 = 70% of the predicted value 7. Negative pregnancy test (urine) for female participants of childbearing potential. Exclusion Criteria: 1. Current or former smoker with >10-pack-year history 2. Current or previous history of lung disease other than mild stable allergic asthma 3. Significant systemic disease, including history of current malignancy or autoimmune disease 4. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) 5. Previous randomisation in the present study. Re-screening (Week -1) for FEV1 and AHR is permitted once for each test. 6. Participation in another clinical study with an investigational product during the last 30 days or 5 half-lives of the drug (whichever is longer) 7. Use of any medications for treatment of asthma other than prophylactic short-acting ß2-agonists, or use of short-acting ß2-agonists for relief of symptoms less than once weekly. 8. Participants with known hypersensitivity to tezepelumab or any of the excipients of the product. 9. Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening 10. Known to have tested positive for human immunodeficiency virus 11. Known history of drug or alcohol abuse within 1 year of screening 12. For women only - currently pregnant (confirmed with positive pregnancy test) or breast feeding. 13. Unwillingness or inability to comply with the study protocol for any other reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tezepelumab
tezepelumab 210 mg sc q4wks for 20 weeks
Placebo
placebo sc q4wks for 20 weeks

Locations

Country Name City State
Canada McMaster University Hamilton Ontario
Canada University of Saskatchewan Saskatoon Saskatchewan

Sponsors (2)

Lead Sponsor Collaborator
McMaster University University of Saskatchewan

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Methacholine PD20 The provocative dose of methacholine causing 20% fall in FEV1 Week -1 to Week 24
Secondary Dose response ratio to mannitol The mannitol dose response ratio calculated by dividing the total cumulative dose by the % fall in FEV1 at that dose. Week -1 to Week 24
Secondary Mast cell tryptase levels. Level of mast cell-derived tryptase in blood and urine at Week 24. Week -1 to Week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Completed NCT03563521 - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed NCT02990117 - ICS Treatment Compliance of Asthma Patients
Completed NCT03468790 - Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. Phase 3
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT03455959 - Lung-Resident Memory Th2 Cells in Asthma N/A
Not yet recruiting NCT05352126 - Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma. N/A
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Not yet recruiting NCT06027073 - Biologics and Sublingual Immunotherapy Phase 4
Recruiting NCT05720325 - Dupilumab Effects Against Aeroallergen Challenge Phase 2
Completed NCT03112577 - Study of REGN3500 and Dupilumab in Patients With Asthma Phase 1
Recruiting NCT04891237 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen Phase 3
Terminated NCT02953106 - Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis Phase 4
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT03705325 - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer N/A
Recruiting NCT05478824 - IL13 Signaling in Allergic Asthma
Withdrawn NCT04035109 - Anakinra as a Rescue Treatment for Allergic Inflammation Phase 1/Phase 2
Suspended NCT04109807 - Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ) N/A
Recruiting NCT03983603 - Plant Stanol Esters and Preventing Asthma Symptoms N/A